COVID-19 cure: Gilead says additional data on antiviral remdesivir shows improved clinical recovery

By: |
Published: July 10, 2020 6:57 PM

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.

Remdesivir, Coronavirus, COVID-19, Coronavirus drug, COVID-19 drug, Cipla, antiviral drug, Hetero, United States Food and Drug Administration, USFDA, Emergency Use Authorisation, EUA, Drug Controller General of India, DCGI, Jubilant Life Sciences, Gilead Sciences IncFindings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company.

Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.

The company said the finding requires confirmation in prospective clinical trials.

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.

Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company
said.

The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.

Gilead shares were up nearly 2% at $76.14 in trading before the bell.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19 tests in India cross 2-crore mark
2UK rolls out 2 new rapid COVID-19 tests
3Three Mantras for Coronavirus control: 2 Surveys, 2 testings and treatment at proper place